These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 14763161)

  • 21. Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling.
    Mitsiades CS; Mitsiades N
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):487-99. PubMed ID: 16001956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of the MEK/MAPK signal transduction pathway strongly impairs the growth of Flt3-ITD cells.
    Takahashi S
    Am J Hematol; 2006 Feb; 81(2):154-5. PubMed ID: 16432846
    [No Abstract]   [Full Text] [Related]  

  • 23. Cell-specific activation profile of extracellular signal-regulated kinase 1/2, Jun N-terminal kinase, and p38 mitogen-activated protein kinases in asthmatic airways.
    Liu W; Liang Q; Balzar S; Wenzel S; Gorska M; Alam R
    J Allergy Clin Immunol; 2008 Apr; 121(4):893-902.e2. PubMed ID: 18395552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways.
    Dobbin E; Graham C; Corrigan PM; Thomas KG; Freeburn RW; Wheadon H
    Exp Hematol; 2009 Jan; 37(1):111-121. PubMed ID: 19100521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advancing the treatment of hematologic malignancies through the development of targeted interventions.
    Tallman MS
    Semin Hematol; 2002 Oct; 39(4 Suppl 3):1-5. PubMed ID: 12447845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
    Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
    Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical aspects and therapeutic perspectives of acute and chronic leukemias.
    Hiddemann W; Griesinger F
    Curr Opin Oncol; 1993 Jan; 5(1):13-25. PubMed ID: 8427885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner.
    Krysan K; Reckamp KL; Dalwadi H; Sharma S; Rozengurt E; Dohadwala M; Dubinett SM
    Cancer Res; 2005 Jul; 65(14):6275-81. PubMed ID: 16024629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.
    Vega MI; Huerta-Yepaz S; Garban H; Jazirehi A; Emmanouilides C; Bonavida B
    Oncogene; 2004 Apr; 23(20):3530-40. PubMed ID: 15077178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.
    Toschi L; Jänne PA
    Clin Cancer Res; 2008 Oct; 14(19):5941-6. PubMed ID: 18829470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond.
    Sullivan RJ; Atkins MB
    Expert Opin Investig Drugs; 2010 Oct; 19(10):1205-16. PubMed ID: 20687784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies.
    Ravandi F; Talpaz M; Estrov Z
    Clin Cancer Res; 2003 Feb; 9(2):535-50. PubMed ID: 12576416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EPHA3 as a novel therapeutic target in the hematological malignancies.
    Keane N; Freeman C; Swords R; Giles FJ
    Expert Rev Hematol; 2012 Jun; 5(3):325-40. PubMed ID: 22780212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.
    Zhu N; Xiao H; Wang LM; Fu S; Zhao C; Huang H
    Future Oncol; 2015; 11(4):659-73. PubMed ID: 25686120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hematologic malignancies /pediatric malignancies-current status of molecular target therapy for hematologic cancer].
    Usui N
    Gan To Kagaku Ryoho; 2010 May; 37(5):805. PubMed ID: 20524247
    [No Abstract]   [Full Text] [Related]  

  • 36. Exploiting inhibitor of apoptosis proteins as therapeutic targets in hematological malignancies.
    Fulda S
    Leukemia; 2012 Jun; 26(6):1155-65. PubMed ID: 22230799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies.
    Wadleigh M; DeAngelo DJ; Griffin JD; Stone RM
    Blood; 2005 Jan; 105(1):22-30. PubMed ID: 15358622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New chemotherapeutics strategies for the treatment of indolent lymphoid malignancies.
    Cheson BD
    Semin Hematol; 1999 Oct; 36(4 Suppl 5):26-33. PubMed ID: 10528913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal antibodies in hematological malignancies: past, present and future.
    Tazi I; Nafil H; Mahmal L
    J Cancer Res Ther; 2011; 7(4):399-407. PubMed ID: 22269399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simultaneous interruption of signal transduction and cell cycle regulatory pathways: implications for new approaches to the treatment of childhood leukemias.
    Grant S; Dent P
    Curr Drug Targets; 2007 Jun; 8(6):751-9. PubMed ID: 17584030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.